The legal scrutiny centers on whether these proposed deals prioritize insider benefits over the value delivered to ordinary shareholders. For CBIZ, Inc., the investigation focuses on its pending $55.00-per-share cash sale to Grant Thornton Advisors LLC. Similarly, Safety Insurance Group Inc. faces questions regarding its $105.00-per-share cash acquisition by an affiliate of Mapfre S.A.

In the case of Neuphoria Therapeutics Inc., the firm is examining the structure of the merger with Scancell Holdings plc, which would leave Neuphoria investors with a 14.5% stake in the combined entity. Halper Sadeh attorneys are evaluating whether these transactions impose restrictive terms that discourage superior competing offers. The firm represents a global base of investors and is currently seeking additional disclosures or increased consideration for those holding equity in these companies.